Bijan Salehizadeh, MD
Dr. Salehizadeh has over 15 years of healthcare operating and investment experience. Prior to co-founding NaviMed Capital, he was a General Partner at Highland Capital Partners, where he focused on growth stage healthcare investments.
Prior to joining Highland Capital Partners in 2004, Dr. Salehizadeh spent several years in a variety of healthcare operational roles at publicly traded and emerging growth companies.
Dr. Salehizadeh is currently on the Board of Directors of CenterPointe Behavioral Health System, Velocity Clinical Research, and OPN Healthcare. He also serves as a member of the Board of Directors of Auris Health and Lumere (formerly Procured Health). Dr. Salehizadeh previously served on the Board of Directors of several companies including BÄRRX (sold to Covidien), Hyperion Therapeutics (IPO; sold to Horizon plc for $1.1 billion), and Opgen (IPO). In addition, he has sourced or been actively involved in Highland Capital Partners’ investments in AVEO (IPO), Baronova, Conor Medsystems (IPO; sold to Johnson & Johnson for $1.4 billion), kyruus, and Pharmaca Integrative Pharmacy.
Dr. Salehizadeh holds an AB in Molecular Biology from Princeton University, an MD and Master’s in Science in Health Policy from Columbia University, and an MBA from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.